Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in liver transplant recipients
Completed
- Conditions
- Immunogenicity and safety of SARS-CoV-2 vaccine in liver transplant recipientsliver transplant, vaccine, COVID-19, SARS-CoV-2, safety
- Registration Number
- TCTR20210526004
- Lead Sponsor
- Faculty of medicine, Chulalongkorn university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Liver transplant recipients who fulfil
1. Liver transplantation more than 3 months
2. No acute cellular rejection within 1 month
Exclusion Criteria
1. History of SARS-CoV-2 infection
2. Pregnancy or lactation
3. Anaphylaxis to COVID-19 vaccine
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity of vaccine 1 and 3 months after primary vaccination & 1 month after booster dose Neutralizing antibody and t-cell specific response
- Secondary Outcome Measures
Name Time Method Safety of vaccine 1 and 3 months after primary vaccination & 1 month after booster dose Patient reported adverse events